Mark K. Slifka, Ph.D.
President and CSO

Dr. Slifka has published primary research articles in prestigious medical journals including Immunity, Nature, Nature Medicine, and the New England Journal of Medicine. He has been quoted in >200 news articles including leading newspapers such as USA Today and the Washington Post. Dr. Slifka has served on academic review panels for the National Institutes of Health, the Canadian Institutes of Health, the Austrian Fund, the Israel Science Foundation, the Israel National Institute for Health Policy & Health Services and the Howard Hughes Medical Institute as well as serving as a pro bono consultant on vaccines and infectious diseases for ABC News. Dr. Slifka obtained his Ph.D. at the UCLA School of Medicine and currently holds a joint faculty position as an Associate Professor at Oregon Health & Science University and the Oregon National Primate Research Center in addition to his role as President and CSO of Najit Technologies, Inc. This close association with academic research institutions has played an important role in the early success of Najit Technologies by providing critical opportunities for advanced research collaborations.

Ian J. Amanna, PhD.
Associate Vice President

Dr. Amanna received his Ph.D. from the Department of Biochemistry at the University of Wisconsin-Madison, followed by a post-doctoral fellowship at the OHSU Vaccine & Gene Therapy Institute (VGTI) in Beaverton, OR. Dr. Amanna was originally recruited to NTI as a Director of Research in 2007 and in 2010 he was promoted to Associate Vice President. His broad scientific background includes investigations into gene therapy, primary immune deficiencies, and the duration of immunity following vaccination. His primary publication on the duration of vaccine-induced immunity published in the New England Journal of Medicine (Amanna et al. NEJM 2007; 1903-15) was ranked by the Amedeo Medical Literature Service as one of the top 10 most influential papers published in 2007 (http://www.amedeoprize.org/).